

Field Name	Field Description
Prior Authorization Group Description	Veklury (remdesivir)
Drugs	<u>Veklury (remdesivir)</u>
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), and the Drug Package Insert (PPI).
Exclusion Criteria	N/A
Required Medical Information	See “Other Criteria”
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	<u>Labeled Use: 10 days</u> <u>Emergency Use Authorization: If all of the conditions are met, the request will be approved for a duration consistent with the fact sheet for health care providers associated with the current emergency use authorization.</u>
Other Criteria	<u>Labeled Use:</u> <u>Veklury will be approved when all of the following criteria are met:</u> <ul style="list-style-type: none"> • <u>Diagnosis of COVID-19</u> • <u>Patient is ≥12 years of age</u> • <u>Patient weighs at least 40kg</u> • <u>Patient is hospitalized</u> <u>Emergency Use Authorization:</u> Use is consistent with the <u>current</u> terms and conditions of the emergency use authorization granted by the US Food and Drug Administration. <u>FDA Emergency Use Authorization Letter:</u> https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fda-authorization-letter-01may2020.pdf?la=en&hash=1333AAA128ECE91DDBB9BC4F9467C843
Revision/Review Date <u>7/2020</u> <u>10/2020</u>	Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.

References:

1. **Veklury (remdesivir) [prescribing information]. Gilead, Foster City, CA; October, 2020.**

2. [ClinicalTrials.gov](https://clinicaltrials.gov/). U.S. National Institutes of Health. Available at: <https://clinicaltrials.gov/>. Accessed on October 23, 2020.
3. [Pubmed.gov](https://www.ncbi.nlm.nih.gov/pubmed). U.S. National Library of Medicine, National Institutes of Health. Available at: <https://www.ncbi.nlm.nih.gov/pubmed>. Accessed on October 23, 2020.
4. [U.S. Food and Drug Administration](http://www.fda.gov/). U.S. Department of Health and Human Services. Available at: <http://www.fda.gov/>. Accessed on October 23, 2020.
5. [Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Oct 8;NEJMoa2007764. doi: 10.1056/NEJMoa2007764.](#)
6. [Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27;NEJMoa2015301. doi: 10.1056/NEJMoa2015301.](#)
7. [Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324\(11\):1048-1057. doi: 10.1001/jama.2020.16349.](#)